Premium
A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis
Author(s) -
HAY R.J.,
CLAYTON Y.M.,
GRIFFITHS W.A.D.,
DOWD P.M.
Publication year - 1985
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1985.tb02338.x
Subject(s) - ketoconazole , griseofulvin , medicine , tinea capitis , dermatology , fluconazole , mycosis , trichophyton , surgery , antifungal
SUMMARY The merits of oral ketoconazole and griseofulvin in dermatophytosis have been compared in a double blind study on 74 patients with 152 infected sites. The initial daily doses were 200 mg and 500 mg respectively, but these were doubled after 3 months if there was an inadequate clinical response. Treatment was continued either until clinical and mycological remission was achieved or a year of therapy had been given. Seventy‐five percent (total 80) and 74% (total 72) of all infected sites treated with ketoconazole and griseofulvin respectively were cleared of infection. However, in toe nail infections the respective cure rates were only 21% and 17%. Ketoconazole appeared to act more rapidly in curing tinea corporis or tinea cruris due to Trichophyton rubrum , whereas griseofulvin was superior in T. interdigitale infections. No serious side‐effects were encountered in either treatment group. In view of the slight risk of drug‐induced hepatitis, ketoconazole is best reserved as a second‐line drug for toe nail infections unless there are specific indications, such as griseofulvin intolerance. In these cases liver function tests should be monitored regularly throughout therapy.